Clinical Monitoring Reduces Myeloma-Related Complications in Precursor Plasma Cell Disorders

Overview

In a retrospective study of 415 multiple myeloma (MM) patients, those with a prior diagnosis of precursor plasma cell disorders (pPCD) such as MGUS or smoldering MM had significantly fewer myeloma-related complications at diagnosis. Clinical monitoring was associated with earlier detection, reduced symptom duration, and lower healthcare utilization compared to patients without known precursor disorders.

Background

Multiple myeloma is consistently preceded by asymptomatic precursor states including MGUS and smoldering multiple myeloma. MGUS prevalence is high in older adults, making early detection and longitudinal follow-up increasingly important. Prior studies have linked known precursor diagnoses to improved survival in MM, but data on morbidity and patient-centered outcomes remain limited. This study aimed to evaluate differences in clinical complications and healthcare utilization between MM patients with and without prior precursor plasma cell disorder diagnoses.

Data Highlights

Key Findings

• MM patients with prior pPCD diagnosis had significantly shorter symptom duration before MM diagnosis (median 4.5 vs 7.6 months, p < 0.001).
• Lower rates of hypercalcemia (6% vs 13%), renal insufficiency (11% vs 23%), anemia (35% vs 65%), and osteolytic lesions (45% vs 59%) were observed in pPCD patients.
• pPCD patients experienced fewer bone pain symptoms, pathologic fractures, cord compression events, dialysis requirements, and red blood cell transfusions at MM diagnosis.
• Healthcare utilization prior to MM diagnosis was reduced in pPCD patients, with fewer emergency department visits (37% vs 64%) and hospitalizations (35% vs 57%).
• Multivariable analysis showed a 71% reduction in odds of presenting with clinically significant myeloma-defining events in pPCD patients (OR 0.29, 95% CI 0.18–0.47, p < 0.001).
• pPCD patients were more likely to be diagnosed at earlier ISS stages (I/II), suggesting earlier disease detection through clinical monitoring.

Clinical Implications

Structured clinical monitoring of patients with precursor plasma cell disorders enables earlier detection of multiple myeloma and reduces the incidence of severe myeloma-related complications. Regular hematologic follow-up facilitates timely intervention, potentially preventing irreversible organ damage and decreasing healthcare resource utilization. These findings support the integration of routine surveillance protocols for MGUS and smoldering MM patients in clinical practice.

Conclusion

Prior diagnosis and clinical monitoring of precursor plasma cell disorders are associated with reduced myeloma-related morbidity and earlier stage at MM diagnosis. This underscores the clinical value of early detection and longitudinal follow-up in improving patient outcomes.

References

1. Kyle et al. 2007 -- Prevalence of MGUS in older adults
2. Landgren et al. 2014 -- Improved survival in MM with known MGUS
3. Rajkumar et al. 2014 -- IMWG criteria for SMM risk stratification
4. Korde et al. 2020 -- Early intervention in high-risk SMM
5. Ottawa Hospital Research Ethics Board -- Study approval